- Array to receive global rights from Novartis to innovative BRAF inhibitor -- Novartis to conduct and/or substantially fund ongoing clinical studies, including COLUMBUS -- Agreement subject to ...

SEATTLE and BOULDER, Colo., May 30, 2013 /PRNewswire/ -- Oncothyreon Inc. (NASDAQ: ONTY) and Array BioPharma Inc. (NASDAQ: ARRY) today announced that they will collaborate to develop and commercialize ...

As previously announced, Array will hold a teleconference on November 7, 2025, at 9:00 a.m. CST. Listen to the call live via the Events & Presentations page of investors.arrayinc.com. Array Digital ...

In addition to the surprising revelation that our chromosomes harbor fewer genes than originally predicted, the Human Genome Project also unveiled that all individuals share approximately 99.9% of ...

Far Left: Mercedes Cooper; Top Row: Tammy Garnes, Allison Biggs, Dee Tuck; Bottom Row: Janae Desire, Sharon Liggins, Montserrat Gomez Courtesy of ARRAY As Ava DuVernay‘s ARRAY nears its 10th ...

Kevin Koch, Ph.D., has resigned as president and CSO of Array BioPharma “to pursue other opportunities,” the company said today, offering no further explanation. “The board and executive team thank Dr ...

ARRY-520 demonstrated single agent activity in heavily pretreated patients, with 19 months median Overall Survival and a 16% Overall Response Rate. These results are similar to those for recently ...

BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (NASDAQ: ARRY) announced today that the strategic alliance between Array and Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), ...

AFCF is a non-GAAP measure defined as Net income from continuing operations adjusted for the items set forth in the reconciliation below. AFCF is not a measure of financial performance under GAAP and ...